

## RESEARCH ARTICLE

# *miR-142-3p* balances proliferation and differentiation of mesenchymal cells during lung development

Gianni Carraro<sup>1</sup>, Amit Shrestha<sup>1</sup>, Jana Rostkovius<sup>1</sup>, Adriana Contreras<sup>2,3</sup>, Cho-Ming Chao<sup>1</sup>, Elie El Agha<sup>1</sup>, Breanne MacKenzie<sup>1</sup>, Salma Dilai<sup>1</sup>, Diego Guidolin<sup>4</sup>, Makoto Mark Taketo<sup>5</sup>, Andreas Günther<sup>1</sup>, Maya E. Kumar<sup>6</sup>, Werner Seeger<sup>1,3</sup>, Stijn De Langhe<sup>7,8</sup>, Guillermo Barreto<sup>2,3</sup> and Saverio Bellusci<sup>1,9,\*</sup>

**ABSTRACT**

The regulation of the balance between proliferation and differentiation in the mesenchymal compartment of the lung is largely uncharacterized, unlike its epithelial counterpart. In this study, we determined that *miR-142-3p* contributes to the proper proliferation of mesenchymal progenitors by controlling the level of WNT signaling. *miR-142-3p* can physically bind to adenomatous polyposis coli mRNA, functioning to regulate its expression level. In *miR-142-3p* loss-of-function experiments, proliferation of parabronchial smooth muscle cell progenitors is significantly impaired, leading to premature differentiation. Activation of WNT signaling in the mesenchyme, or *Apc* loss of function, can both rescue *miR-142-3p* knockdown. These findings show that in the embryonic lung mesenchyme, the microRNA machinery modulates the level of WNT signaling, adding an extra layer of control in the feedback loop between FGFR2C and  $\beta$ -catenin-mediated WNT signaling.

**KEY WORDS:** WNT signaling, Mesenchymal cell, miRNA

**INTRODUCTION**

During lung organogenesis, mesenchymal cells undergo active proliferation to support the continuous growth of the organ. Simultaneously, many cells are actively differentiating into the specific cell types that will populate the adult lung – such as parabronchial and vascular smooth muscle cells, pericytes, nerve cells, lipofibroblasts and interstitial fibroblasts. A specific balance between proliferation and differentiation must exist to guarantee the formation of a functional lung. For example, parabronchial smooth muscle cell (PBSMC) progenitors are kept undifferentiated in the sub-mesothelial mesenchyme while starting to differentiate more proximally (Mailleux et al., 2005). It is crucial to understand this delicate balance in order to better

characterize lung diseases involving altered mesenchymal proliferation and differentiation.

WNT signaling plays a crucial role in proper proliferation of mesenchymal cells during lung development (De Langhe et al., 2008; Yin et al., 2008). In particular, through  $\beta$ -catenin (CTNNB1), it promotes G1 phase progression by activation of downstream target genes such as *Myc* and cyclin D1 (*Ccnd1*) (Niehrs and Acebron, 2012). High WNT signaling and *Myc* activation are associated with the hyper-proliferative state of cancer of many organs, including the lung (He et al., 1998; van de Wetering et al., 2002; Van Scoyk et al., 2008).

A main regulator of WNT signaling is adenomatous polyposis coli (APC), which can directly bind to CTNNB1, antagonizing the interaction with T-cell factor (TCF). In combination with AXIN and GSK3B, APC induces ubiquitylation and degradation of CTNNB1 (Clevers and Nusse, 2012). Loss of *Apc* leads to accumulation of CTNNB1 in the nucleus and hyperactivation of WNT signaling. *Apc* was first identified as a tumor suppressor gene that, upon mutation, causes intestinal cancer (Grodin et al., 1991). APC can also control cytoskeleton structure and cell migration by binding microtubules and actin filaments. For example, loss of *Apc* in the small intestine reduces the migration of epithelial cells and promotes the formation of polyps (Oshima et al., 1997).

Specific microRNAs (miRNAs) have been implicated in both lung development and disease (Jiang et al., 2010; Ornitz and Yin, 2012). In the epithelium, mice with loss of function of members of the *miR-17* family show early lethality and hypoplastic lungs, whereas overexpression results in hyperproliferation and inhibition of differentiation of epithelial progenitors (Lu et al., 2007; Ventura et al., 2008). The *miR-302* family regulates epithelial progenitor proliferation and differentiation, as well as apical-basal polarity (Tian et al., 2011). Recently, *miR-375* has been shown to target WNT signaling and regulate the differentiation of alveolar epithelial cells by controlling the expression of the frizzled 8 gene (Wang et al., 2013). However, miRNAs regulating WNT signaling in the lung mesenchyme have yet to be reported. *miR-142-3p* is a miRNA first identified for its function in the development of the lymphoid system (Neilson et al., 2007), and was subsequently implicated in leukemia (Lv et al., 2012). In the lung, *miR-142-3p* is involved in malignancy and has been reported to be an early marker for aggressive and recurrent lung adenocarcinomas (Kaduthanam et al., 2013).

Herein, we detail *miR-142-3p* as a specific regulator of *Apc* expression in the mesenchyme. Using a loss-of-function approach, we analyzed the role of the *miR-142-3p-Apc* axis in mesenchymal cells. Using both pharmacological and genetic tools, we tested whether WNT signaling upregulation is sufficient to rescue *miR-142-3p* loss-of-function and whether *Apc* is a crucial target of this miRNA.

<sup>1</sup>University of Giessen Lung Center, Excellence Cluster in Cardio-Pulmonary Systems, member of the German Lung Center (DZL), Department of Internal Medicine II, Aulweg 130, 35392 Giessen, Germany. <sup>2</sup>LOEWE Research Group Lung Cancer Epigenetic, Max Planck Institute for Heart and Lung Research, Member of the German Lung Center (DZL), 61231 Bad Nauheim, Germany. <sup>3</sup>Department of Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Member of the German Lung Center (DZL), 61231 Bad Nauheim, Germany. <sup>4</sup>University of Padova, Department of Molecular Medicine, 35121 Padova, Italy. <sup>5</sup>Department of Pharmacology, Kyoto University Graduate School of Medicine, Yoshida-Konoé-cho, Sakyo-ku, Kyoto 606-8501, Japan. <sup>6</sup>Department of Biochemistry and HHMI, Stanford University School of Medicine, Stanford, CA 94305, USA. <sup>7</sup>Department of Pediatrics, National Jewish Health, Denver, CO 80206, USA. <sup>8</sup>Department of Cellular and Developmental Biology, University of Colorado Denver, Aurora, CO 80045, USA. <sup>9</sup>Developmental Biology Program, Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.

\*Author for correspondence (saverio.bellusci@innere.med.uni-giessen.de)


Received 12 November 2013; Accepted 15 January 2014

## RESULTS

***miR-142-3p* regulates mesenchymal cell proliferation and differentiation**

In order to identify miRNAs with a specific function in the lung mesenchyme, we performed a microarray analysis on embryonic mouse lung tissue (Fig. 1A). We observed that 5 and 14 miRNAs were highly expressed, respectively, in the embryonic lung mesenchyme and the epithelium. Among those in the epithelium, we found several members of the miR-200 family. These miRNAs are involved in epithelial to mesenchymal transition (Brabletz and Brabletz, 2010), and their high expression in the embryonic epithelium suggests they may play a role in the plasticity of the branching tips during lung morphogenesis.

An *in vitro* loss of function (LOF) assay was optimized to functionally characterize the newly identified miRNAs in the mesenchyme. Embryonic day (E) 11.5 lung explants were grown in the presence of vivo-morpholino against either a scrambled sequence or a specific miRNA. We selected *miR-126* as a positive control for our LOF assay because it was previously described to regulate vasculature formation. Using vivo-morpholino against *miR-126* (*mo126*), we were able to impair vasculature formation (supplementary material Fig. S1A-I,J-M,R;  $n=3$ ,  $P\leq 0.05$ ), thus mimicking the phenotype observed in the *miR-126* knockdown zebrafish (Fish et al., 2008). As a negative control we selected *miR-144*, because its inactivation does not lead to a specific lung phenotype in mice (Rasmussen et al., 2010). In our LOF assay,



**Fig. 1. *miR-142-3p* regulates mesenchymal cells proliferation and differentiation.** (A) MicroRNA microarray shows miRNAs differentially expressed in E12.5 lung epithelium (blue) versus mesenchyme (red). *miR-142-3p* (arrowhead) is specifically upregulated in the embryonic lung mesenchyme. (B) Expression of *miR-142-3p* in the epithelium and mesenchyme of E12.5 lungs analyzed by qPCR. (C-J) *miR-142-3p* LOF assay on E11.5 lung explants treated with scramble vivo-morpholino (scra; C-F) and *miR-142-3p* vivo-morpholino (mo142; G-J). (K) Expression of *miR-142-3p* detected by qPCR 48 hours after treatment with mo142. (L-N) Morphometric analysis 48 hours after *miR-142-3p* LOF assay on E11.5 lung explants. (O-R) Immunostaining for KI67 showing cell proliferation in scra- (O,P) and mo142 (Q,R)-treated E11.5 lung explants, and quantification of proliferation in the epithelium and mesenchyme (S). (T-W) Immunostaining for ACTA2 showing smooth muscle cells at the tips of scra- (T,U) and mo142 (V,W)-treated E11.5 lung explants. Dashed boxes in O, Q, T and V indicate the magnified areas in P, R, U and W, respectively. White arrowheads indicate ectopic ACTA2 expression. (X) Quantification of ACTA2 expression at the tip of the lung explants from the previous experiment. Scale bars: 250  $\mu$ m (C,E,G,I); 50  $\mu$ m (D,F,H,J); 100  $\mu$ m (O,Q,T,V); 25  $\mu$ m (P,R,U,W). Data are means  $\pm$  s.d. See also supplementary material Fig. S1 and Movie 1.

*mol144* did not produce any branching defect or alteration of proliferation (supplementary material Fig. S1A-I,N-Q,S;  $n \geq 3$ ,  $P < 0.05$ ). These results indicate that our LOF assay is an effective tool for the identification of functionally important miRNAs.

Using this assay we tested whether *miR-142-3p* plays a functional role in the lung mesenchyme. We first confirmed that *miR-142-3p* is highly expressed in the embryonic lung mesenchyme by qPCR (Fig. 1B;  $n=3$ ,  $P < 0.05$ ). Then the LOF assay for *miR-142-3p* was conducted. qPCR showed reduced *miR-142-3p* levels (Fig. 1K;  $n=3$ ,  $P < 0.05$ ) associated with impaired branching (Fig. 1C-J). The number of branching points was decreased (Fig. 1L;  $n=10$ ,  $P < 0.05$ ) and the lung tips had the tendency to elongate instead of bifurcate, thus resulting in a decreased number of terminal buds (Fig. 1M;  $n=10$ ,  $P < 0.05$ ; supplementary material Movie 1). Reduction of lung growth, illustrated by a diminished total lung area (Fig. 1N;  $n=10$ ,  $P < 0.05$ ), was observed. Immunostaining for KI67 at 24 hours post-treatment showed a striking reduction of proliferation that, interestingly, was evident in the mesenchyme but not in the epithelium (Fig. 1O-S;  $n=4$ ,  $P < 0.05$ ). Furthermore, inhibition of *miR-142-3p* led to ectopic expression of the SMC marker alpha-SMA (ACTA2) in the distal mesenchyme (Fig. 1T-X;  $n=3$ ,  $P < 0.05$ ). Together, these results suggest a function for *miR-142-3p* in the control of proliferation and differentiation of the lung mesenchyme.

#### **miR-142-3p regulates WNT signaling by directly controlling *Apc* expression**

To determine whether specific signaling pathways are involved in *miR-142-3p* regulation of mesenchymal cell proliferation, we utilized the prediction software miRTar and grouped the candidate genes by pathway. Interestingly, WNT signaling was the first hit (Table 1). To verify that WNT signaling was regulated by *miR-142-3p* in the mesenchyme, we performed a LOF assay on E11.5 lung explants obtained from a WNT reporter mouse line carrying  $\beta$ -galactosidase ( $\beta$ -Gal) expression under the endogenous control of the *Axin2* promoter (*Axin2<sup>lacZ</sup>* mice). Staining of  $\beta$ -Gal after 24 hours showed a specific inhibition of WNT signaling in the distal mesenchyme (Fig. 2A-E;  $n=3$ ,  $P < 0.05$ ). Because miRNAs are negative regulators of gene expression, we aimed to identify WNT genes upregulated upon *miR-142-3p* knockdown. A qPCR screening for members of the WNT signaling pathway expressed in the lung was carried out at 12 hours and at 24 hours during our LOF assay. At 12 hours, we observed that *Apc* – a gene encoding a negative regulator of WNT signaling – was highly expressed. At 24 hours, *Apc* was still upregulated while other members were downregulated (Fig. 2F,G). Analysis of LEF1 expression by immunofluorescence confirmed a strong reduction of mesenchymal WNT signaling 24 hours after LOF assay (Fig. 2H-K). We reasoned that since the effect on proliferation, branching and WNT signaling were visible starting at 24 hours, the upregulation of *Apc* at 12 hours is an early event that could contribute to the observed phenotype. Immunofluorescence

analysis for APC at 12 hours (data not shown) and at 24 hours after our LOF assay confirmed an increase of mesenchymal APC at protein level (Fig. 2L-O). At 12 hours epithelial APC was unchanged (data not shown), but at 24 hours there was a reduction in APC. Considering the timing of this reduction and the fact that *miR-142-3p* is expressed in the mesenchyme, we assume this effect was secondary to the mesenchymal phenotype. Interestingly, *Apc* was among the five most highly ranked WNT signaling genes (*Apc*, *Tbx1*, *Rock2*, *Rac1*, *Senp2*) that were predicted as targets of *miR-142-3p* (Table 1). As *Tbx1*, *Rock2* and *Rac1* were not included in our first screening, we analyzed their expression 12 hours after the LOF assay. Although the expression of *Apc* and *Senp2* was enhanced, expression of *Tbx1*, *Rock2* and *Rac1* showed no significant change (Fig. 2P;  $n=3$ ,  $P < 0.05$ ). The expression of *Senp2* was reduced at 24 hours (Fig. 2G), suggesting that the modulation of its expression by *miR-142-3p* may not be as specific as for *Apc*.

We then wanted to determine whether *miR-142-3p* was able to physically bind the mRNA of its predicted target genes. For this purpose, we performed a pull-down experiment using a biotinylated *miR-142-3p* followed by qPCR to detect specific binding. The biotinylated *miR-142-3p* was able to cause overexpression of WNT signaling target genes such as *Myc* and *Fgfr2* (supplementary material Fig. S2A,B), suggesting that biotinylation was not altering the property of *miR-142-3p*. In this assay, performed on a lung mesenchymal cell line (MLg cells), *Apc* was enriched more than six times compared with the control (Fig. 2M;  $n=3$ ,  $P < 0.05$ ). The same assay was reproduced in MFLM4 and HEK293 cells, suggesting that indeed *miR-142-3p* directly interact with *Apc* to regulate its expression (supplementary material Fig. S2C;  $n=3$ ,  $P < 0.05$ ). We further wanted to determine if *miR-142-3p* was binding *Apc* by specifically interacting with the predicted binding sites located at the 3'-UTR of *Apc* mRNA. For this purpose, we cloned *Apc* seed sites into two luciferase (Luc) reporter plasmids containing either a mutated binding site or a wild-type locus. We observed that the ability of *miR-142-3p* to target *Apc* was compromised in the presence of the mutated 3'UTR (Fig. 2N;  $n=3$ ,  $P < 0.05$ ).


#### **miR-142-3p downregulation leads to parabronchial smooth muscle cell progenitor differentiation**

APC is a negative regulator of WNT signaling and, as a direct target of *miR-142-3p*, its increase can explain the drop in WNT signaling following *miR-142-3p* knockdown. In the embryonic lung mesenchyme, WNT, in combination with FGF signaling, creates a positive feedback loop. In fact, lack of contribution from either FGF (specifically FGF9-FGFR2c) or WNT disrupts this delicate equilibrium (Yin et al., 2011). When this system is operational, WNT signaling maintains *Fgfr2c* expression in the mesenchyme allowing mesenchymal growth through the regulation of G1 to S phase transition (De Langhe et al., 2008; Yin et al., 2008). Therefore, we decided to test whether the inhibition of WNT

**Table 1. miR-142-3p targets pathway enrichment**

Target genes	Pathway	P value	Number of matched genes	Number of genes in pathway
<i>APC, TBL1X, SENP2, ROCK2, RAC1</i>	Wnt signaling	4.50E-08	5	182
<i>APC, ROCK2, RAC1</i>	Regulation of actin cytoskeleton	9.19E-04	3	246
<i>APC, RAC1</i>	Colorectal cancer	1.82E-03	2	73
<i>ROCK2, RAC1</i>	Axon guidance	9.25E-03	2	167
<i>ROCK2, RAC1</i>	Leukocyte transendothelial migration	1.15E-02	2	187
<i>ROCK2, RAC1</i>	Chemokine signaling	1.20E-02	2	191
<i>ROCK2, RAC1</i>	Focal adhesion	1.32E-02	2	201
<i>APC, RAC1</i>	Pathways in cancer	5.21E-02	2	415






**Fig. 2. *miR-142-3p* regulates WNT signaling by direct control of *Apc* expression.** (A-E) *miR-142-3p* LOF assay on *Axin2<sup>LacZ</sup>* E11.5 lung explants. Lung explants (A,C) and vibratome sections (B,D) are shown 24 hours after *miR-142-3p* LOF assay. Mesenchymal  $\beta$ -gal is quantified in E. (F,G) Members of the WNT signaling pathway were quantified by qPCR 12 and 24 hours after the *miR-142-3p* LOF assay. (H-K) LEF1 expression 24 hours after the *miR-142-3p* LOF assay. (L-O) APC expression after the *miR-142-3p* LOF assay. Immunofluorescence for APC 24 hours after scra (L,M) and mo142 (N,O) treatment. Dashed boxes indicate the magnified area shown in the panels to the right. Dashed lines in M and O demarcate the epithelium-mesenchyme boundary. (P) Quantification by qPCR of *miR-142-3p* predicted targets 12 hours after *miR-142-3p* LOF assay. (Q) Quantification by qPCR of *miR-142-3p* predicted targets after biotin mRNA-miRNA pull down assay. (R) Luciferase assay for *Apc* seed sequences on MLg cells. Scale bars: 150  $\mu$ m (A,C); 100  $\mu$ m (B,D); 75  $\mu$ m (H,J,L,N); 25  $\mu$ m (I,K,M,O). Data are means  $\pm$  s.d. See also supplementary material Fig. S2.

signaling observed in our *miR-142-3p* LOF assay was associated with perturbation of the FGF-WNT sustained regulation. Indeed, qPCR on E11.5 lung explants showed decreased *Fgfr2c* expression beginning 24 hours into the assay (Fig. 3D-F;  $n=3$ ,  $P<0.05$ ). At 48 h, *Fgfr2c* reduction was associated with a specific decrease in the mesenchyme of phosphorylated ERK (pERK; Fig. 3M-Q;  $n=4$ ,  $P<0.05$ ) and phosphorylated MEK (pMEK; Fig. 3R-V;  $n=3$ ,  $P<0.05$ ). One of the functions of FGF9-FGFR2c signaling in the lung is to keep mesenchymal PBSMC progenitors undifferentiated and proliferating (Yi et al., 2009). Furthermore, we have previously shown that FGF10 is expressed in, and identifies PBSMC progenitors (Mailleux et al., 2005). Analysis by qPCR after the *miR-142-3p* LOF assay showed that *Fgfr2b* expression remained stable,

suggesting that epithelial FGF signaling was unaffected (Fig. 3J-L;  $n=3$ ,  $P<0.05$ ). However, *Fgf10* started decreasing at 24 hours and was significantly reduced at 48 hours (Fig. 3G-I;  $n=3$ ,  $P<0.05$ ). This result suggests that *Fgf10*-positive PBSMC progenitors were specifically affected by the imbalance of FGF-WNT regulation. We therefore decided to analyze the effect of our *miR-142-3p* LOF assay on SMC differentiation. To directly analyze PBSMC progenitors during *miR-142-3p* downregulation, conditional red fluorescent protein (RFP) reporter mice (*RFP<sup>f/f</sup>*) were crossed with mice carrying *Fgf10<sup>CreERT2</sup>*. We will refer to these mice with genotype *Fgf10<sup>CreERT2/+</sup>,RFP<sup>f/+</sup>* as *RFP<sup>Fgf10</sup>*.

Live imaging of *RFP<sup>Fgf10</sup>* E11.5 lung explants treated with *miR-142-3p* vivo-morpholino (mo142; supplementary material Movie 2)




**Fig. 3. Loss of *miR-142-3p* affects mesenchymal FGF signaling.** (A-L) FGF signaling genes were quantified by qPCR. The expression of *Fgf9* (A-C), *Fgfr2c* (D-F), *Fgf10* (G-I) and *Fgfr2b* (J-L) was analyzed at 12, 24 and 48 hours after LOF assay on E11.5 lung explants. (M-Q) Phosphorylated ERK (pPERK) expression was analyzed 24 and 48 hours after LOF assay on E11.5 lung explants. pPERK expression in the epithelium and mesenchyme is shown by immunofluorescence at 48 hours (M-P) and was quantified at 24 and 48 hours (Q). pMEK expression in the epithelium and mesenchyme is shown by immunofluorescence at 48 hours (R-U) and quantified at 24 and 48 hours (V). Dashed boxes indicate the magnified areas in the adjacent panels. Dashed lines in N, P, S and U demarcate the epithelium-mesenchyme boundary. Scale bars: 100  $\mu$ m (M,O,R,T); 50  $\mu$ m (N,P,S,U). Data are means  $\pm$  s.d.

showed that labeled PBSMC progenitors formed ring-like structures, reminiscent of smooth muscle cell phenotype, at the tip of the epithelial buds (Fig. 4A-D). These data are in agreement with the ectopic alpha-SMA (ACTA2) expression at the tip of the epithelial buds during mo142 treatment (Fig. 1T-W). Additionally, in mo142-treated explants, labeled cells displayed reduced motility and proliferation, but in scrambled-treated explants, they were highly motile and proliferative (supplementary material Movie 2; Fig. 4E-G;  $n=3$ ,  $P<0.05$ ). Our results suggest that PBSMC progenitors prematurely differentiate upon mo142 treatment. To further demonstrate that this was due to loss of FGF9-FGFR2c signaling, primary embryonic lung mesenchymal cells were cultured *in vitro* in different experimental conditions. Scrambled-treated primary mesenchymal cells grown in the presence of FGF9 were prevented from differentiating into SMCs (Fig. 4H,I). After *miR-142-3p* knockdown, FGF9 was no longer effective and thus differentiation into SMCs occurred (Fig. 4J-L). The role of *miR-142-3p* in SMC differentiation was further evaluated using a gain of function

approach. We used mesenchymal cells from a mouse lung mesenchymal cell line (MLg cells). Under normal *in vitro* culture conditions, MLg cells differentiate into ACTA2-positive cells. Overexpression of *miR-142-3p* by a synthetic form of *miR-142-3p* that mimics its function (mi142) led to reduced ACTA2 expression and diminished elongation (Fig. 4M-O). Because *Apc* is a specific target for *miR-142-3p* (Fig. 2H-N), we wanted to determine if *Apc* overexpression is sufficient to mimic *miR-142-3p* knockdown. Primary mesenchymal cells isolated from *RFP<sup>Fgf10</sup>* lungs were electroporated with either control plasmids (pGFP) or experimental plasmids overexpressing APC (pAPC). *Apc* overexpression was sufficient to mimic loss of *miR-142-3p*, producing reduced proliferation and motility of PBSMC progenitors (Fig. 4P-V;  $n=3$ ,  $P<0.05$ ; supplementary material Movie 3).

**Constitutive WNT signaling rescues *miR-142-3p* knockdown**  
The inhibition of WNT signaling in the *miR-142-3p* LOF assay prompted us to attempt a rescue experiment in which WNT




**Fig. 4. Loss of *miR-142-3p* leads to lung mesenchyme differentiation.** (A-D) Analysis of *RFP<sup>Fgf10</sup>* lung explants after scra (A,B) and mo142 (C,D) administration, and quantification of cell motility (E,F) and proliferation (G). (H-K) Immunostaining for ACTA2 showing lung primary mesenchymal cells after administration of BSA or FGF9 in the presence of scra (H,I) or mo142 (J,K). (L) Quantification of ACTA2-positive cells. (M,N) MLg cells were analyzed for ACTA2 expression by immunostaining after scra (M) or mi142 (N) administration. (O) Quantification of cellular morphology as a ratio of length to width. (P-S) *RFP<sup>Fgf10</sup>* primary mesenchymal cells were electroporated with a plasmid expressing GFP (pGFP) or APC (pAPC) and analyzed between 0 and 45 hours. (T-V) Quantification of the cell motility (T,U) and proliferation (V) for pGFP- and pAPC-treated cells. Dashed boxes indicate the magnified areas shown in the insets. Dashed lines demarcate the epithelium-mesenchyme boundary. Scale bars: 250 μm (A,C); 50 μm (B,D); 50 μm (H-K insets); 20 μm (H-K main image); 50 μm (M,N); 75 μm (P-S). Data are means ± s.d. See also supplementary material Movies 2 and 3.

signaling was stimulated at different levels of the pathway. We began with WNT3a, a commercially available WNT ligand. Lungs treated with WNT3a display expansion of the epithelium and mesenchyme compared with BSA-treated lungs (data not shown and

supplementary material Fig. S3C,D). Upon *miR-142-3p* attenuation, WNT3a was unable to affect mesenchymal growth (supplementary material Fig. S3A,B,D;  $n=3$ ,  $P<0.05$ ). Similar results were obtained by using FGF9 (Fig. 5A-D;  $n=3$ ,  $P<0.05$ ) and FGF9 in combination





**Fig. 5. Stabilized *Ctnnb1* expression or decreased *Apc* expression in the mesenchyme counteracts the effect of *miR-142-3p* inhibition on proliferation and differentiation.** (A-D) FGF9 (200 ng/ $\mu$ l) was administered to E11.5 lung explants cultured in the presence of scra (A) or mo142 (B), and mesenchyme thickness (C) and epithelial and mesenchymal surfaces (D) were measured. (E) Schematic showing the time line of the experimental treatment. The green and red lines depict tamoxifen and mo142 effects, respectively. (F-O) E11.5 lung explants harboring a mesenchymal stabilized form of *Ctnnb1* obtained by *Tbx4*-driven Cre expression, and control lungs were treated with mo142 and immunostained for ACTA2 (F-I) or pMEK (J-M). Quantification of ACTA2 and pMEK are shown in N and O, respectively. (P-II) E11.5 lung explants with mesenchymal deletion of *Apc* by *Tbx4*-driven Cre expression (P-S) and control lungs (T-W) were treated with mo142 and their morphometry was analyzed (X,Y). Immunostaining for ACTA2 and APC (Z-CC) or Ki67 and APC (DD-GG) from the previous experiment and its relative quantification (HH,II). Dashed boxes indicate the magnified areas in the adjacent panels. Dashed lines demarcate the epithelium-mesenchyme boundary. Scale bars: 250  $\mu$ m (A,B); 75  $\mu$ m (F,H,I,K,L); 25  $\mu$ m (G,I,K,M); 250  $\mu$ m (P,R,T,V); 50  $\mu$ m (Q,S,U,W); 75  $\mu$ m (Z,BB,DD,FF); 25  $\mu$ m (AA,CC,EE,GG). Data are means  $\pm$  s.d. See also supplementary material Fig. S3.

with WNT3a (supplementary material Fig. S3E-H;  $n=3$ ,  $P<0.05$ ). Under these conditions FGF9 still caused expansion of the epithelium. This result further confirms that when *miR-142-3p* expression is inhibited the positive feedback loop between FGF and WNT signaling in the mesenchyme is impaired. To intervene downstream of WNT signaling, we used mice harboring a floxed allele in the *Ctnnb1* gene (*Ctnnb1*<sup>ex3</sup><sup>f/f</sup>) to generate a stable form of *Ctnnb1*. Crossing this line with *Tbx4LME*<sup>CreERT2</sup> mice, we were able to obtain inducible constitutive activation of *Ctnnb1*, specifically

in the mesenchyme. We will refer to the genotype *Tbx4LME*<sup>CreERT2/+</sup>, *Ctnnb1*<sup>(ex3)<sup>f/+</sup></sup> as *Ctnnb1*<sup>f/+;Tbx4</sup>. *Ctnnb1*<sup>f/+;Tbx4</sup> and *Ctnnb1*<sup>f/f</sup> lungs from the same genotype represented WNT-activated and control lungs, respectively, and were used in the LOF assay (Fig. 5E). Lungs from *Tbx4LME*<sup>CreERT2/+</sup> mice injected with tamoxifen intraperitoneally were also used as controls in the LOF assay, showing similar results to the *Ctnnb1*<sup>f/f</sup> lungs (data not shown). Forty-eight hours after the *miR-142-3p* LOF assay, the activation of CTNNB1 signaling in *Ctnnb1*<sup>f/+;Tbx4</sup> lungs, compared

to *Ctnnb1<sup>fl/fl</sup>* lungs (supplementary material Fig. S3M-P), led to the disappearance of mo142-induced MYH11 (supplementary material Fig. S3I-L) and ACTA2 ectopic expression (Fig. 5F-I,N;  $n=3$ ,  $P<0.05$ ) at the tip of the epithelial buds. We also observed increased pMEK expression in mo142-treated *Ctnnb1<sup>fl/+;Tbx4</sup>* compared with *Ctnnb1<sup>fl/fl</sup>* lungs, suggesting recovery of FGF signaling in the mesenchyme (Fig. 5J-M,O;  $n=3$ ,  $P<0.05$ ).

### Reduction of *Apc* expression rescues *miR-142-3p* knockdown

Having identified *Apc* as a direct target of *miR-142-3p*, we decided to test whether reduction of *Apc* by ablation of one of the two copies of the gene was able to rescue the effect of *miR-142-3p* inhibition. For this purpose we used *Apc<sup>fl/fl</sup>* mice crossed with *Tbx4LME<sup>CreERT2/+</sup>* mice. We will refer to the genotype *Tbx4LME<sup>CreERT2/+</sup>; Apc<sup>fl/+</sup>* as *Apc<sup>fl/+;Tbx4</sup>*. *Apc<sup>fl/fl</sup>* lungs were used as controls. *Tbx4LME<sup>CreERT2/+</sup>* were also used as controls with similar results to *Apc<sup>fl/fl</sup>* lungs in the LOF assay (data not shown). Forty-eight hours after the *miR-142-3p* LOF assay, the reduction of APC expression in *Apc<sup>fl/+;Tbx4</sup>* compared with *Apc<sup>fl/fl</sup>* lung explants was confirmed by qPCR (data not shown) and immunohistochemistry (Fig. 5DD-GG). This reduction led to the disappearance of mo142-induced ectopic expression of ACTA2 at the tip of the epithelial buds (Fig. 5Z-CC,HH;  $n=3$ ,  $P<0.05$ ), as well as increased KI67 expression in the mesenchyme (Fig. 5DD-GG,II;  $n=3$ ,  $P<0.05$ ). In addition, *Apc<sup>fl/+;Tbx4</sup>* lungs were able to recover growth and branching (Fig. 5P-Y;  $n=3$ ,  $P<0.05$ ). These results suggest that the inhibition of *Apc* alone is sufficient to counteract *miR-142-3p* knockdown.

### DISCUSSION

In this study we describe a new function of the microRNA machinery in the lung embryonic mesenchyme. We determined that *miR-142-3p* is a crucial regulator of WNT signaling in this compartment. By directly controlling *Apc* expression, *miR-142-3p* can fine-tune its inhibition of WNT signaling. Furthermore, *miR-142-3p* controls proliferation and differentiation of mesenchymal progenitor in the embryonic lung (Fig. 6A,B).

A fine balance between FGF and WNT signaling helps maintain the pool of mesenchymal progenitor cells in the lung embryonic mesenchyme. For example, evidence suggests that FGF9 from the mesothelium can signal to *Fgf10*-positive cells located in the submesothelial mesenchyme to prevent differentiation (Colvin et al., 2001). In this system, WNT signaling helps maintain proper levels of FGF signaling, because reduced WNT signaling creates disequilibrium in the feedback loop that maintains mesenchymal


FGF-WNT signaling (De Langhe et al., 2008; Yin et al., 2011). Here, we found that *miR-142-3p* is implicated in the modulation of the WNT and FGF balance, adding an extra layer of control that increases the robustness of this system.

We show that *miR-142-3p* fulfills this function by directly controlling *Apc* expression, therefore acting as a negative regulator of an inhibitor of WNT signaling. Deregulation of *miR-142-3p* expression uncouples WNT and FGF signaling in the mesenchyme, affecting mesenchymal progenitor cells differentiation. Specifically, the *Fgf10*-positive lineage which contributes to the formation of parabronchial smooth muscle cells is affected by the deregulation of *miR-142-3p* expression, resulting in premature differentiation and proximalization of the mesenchyme.

Recently, *miR-142-3p* was found to control hemangioblast specification and vasculogenesis in *Xenopus* (Nimmo et al., 2013). In our LOF assay we observed impaired angiogenesis of the lung explants, which was associated with enrichment of markers for undifferentiated hemangioblasts such as CD31 (data not shown). This suggests that a similar regulation could also contribute to the vasculogenesis in the lung. It will be interesting to determine if *miR-142-3p* controls similar pathways – for instance WNT signaling – or if the two systems are completely independent.

Although our screening identified *Apc* as a main target of *miR-142-3p*, other genes are likely to be affected. In particular, other members of WNT signaling were found to bind to biotinylated *miR-142-3p* to a lower degree than *Apc*. Nonetheless, rescue experiments with *Apc<sup>Tbx4</sup>* mice showed that the inhibition of *Apc* in the mesenchyme is sufficient to rescue the lung from *miR-142-3p* downregulation, suggesting that *Apc* is a crucial molecule regulated by *miR-142-3p* in the lung mesenchyme. We also found that in the parenchyma of the adult lungs, *miR-142-3p* and APC are mutually exclusive (data not shown). This suggests that the regulation here described may not be limited to the embryonic lung. In addition, our finding is consistent with the observation that inactivation of *Apc* in the lung mesenchyme using a *Tbx4*-rtTA driver mouse line leads to reduced and disorganized smooth muscle cell differentiation in the lung (personal communication from Wei Shi). This suggests that APC per se, has a critical role in the regulation of proliferation, survival, and differentiation of smooth muscle progenitor cells.

In summary, our work shows that *miR-142-3p* is intimately linked to mesenchymal activated WNT signaling by specific regulation of *Apc*. It will be of interest to determine if the *miR-142-3p*-*Apc*- $\beta$ -catenin axis plays a role in lung diseases such as idiopathic pulmonary fibrosis, in which cellular proliferation and differentiation of mesenchymal cells is unbalanced.



**Fig. 6. Schematic of *miR-142-3p* regulation of WNT signaling by direct control of *Apc* expression.** (A) A fine balance of mesenchymal FGF and WNT signaling (a) is necessary to maintain proper mesenchymal proliferation. In this context, APC (b) contributes to control the level of  $\beta$ -catenin (CTNNB1), and *miR-142-3p* (c) controls the inhibitory effect of APC. Changes in *miR-142-3p* expression can therefore modulate the balance between proliferation (A) and differentiation (B) of mesenchymal progenitors. Blue, mesenchymal progenitors; red, differentiated smooth muscle cells.



## MATERIALS AND METHODS

### Mouse strains

C57BL/6 wild-type, *Apc*<sup>flax/+</sup>, *Tomato*<sup>flax/flax</sup> and *Axin2*<sup>lacZ</sup> mice were obtained from Jackson Laboratories. *Fgf10*<sup>CreERT2/+</sup> mice were generated in our laboratory as previously described (El Agha et al., 2012). *Ctnnb1*<sup>(ex3)fl</sup> mice were generated in the Taketo laboratory (Harada et al., 1999). *Tbx4*<sup>LME</sup><sup>CreERT2/+</sup> mice were generated in the Krasnow laboratory (M.E.K., Patrick E. Bogard, F. Hernán Espinoza, Douglas B. Menke, David M. Kingsley and Mark A. Krasnow, unpublished data). For rescue experiments, tamoxifen was administered by intraperitoneal injection (0.1 mg/g of body weight) 24 hours before the LOF assay. Animals were housed at room temperature with a 12 hour/12 hour light/dark cycle and free access to food and water. The Federal Authorities for Animal Research of the Regierungspräsidentium Giessen (Hessen, Germany) approved the study protocol (*miR-142-3p* protocol 52/2012).

### MicroRNA array and qPCR

Epithelium from E12.5 lung buds was isolated as previously described (Carraro et al., 2009); mesenchyme from E12.5 lung buds was physically isolated using 0.12 mm tungsten needles (Fine Science Tools). Total RNA was extracted using a miRNeasy Mini Kit (Qiagen). The quality of the total RNA was verified using an Agilent 2100 Bioanalyzer profile. Total RNA (1000 ng) was labeled with fluorescent Hy3 and Hy5 using the miRCURY LNA Array power labeling kit (Exiqon) following the procedure described by the manufacturer. The labeled RNAs were mixed pair-wise and hybridized to the miRCURY LNA Array version 5th Generation (Exiqon). The hybridization was performed according to the miRCURY LNA array manual using an HS4800 hybridization station (Tecan). The slides were scanned using the Agilent G2565BA Microarray Scanner System (Agilent Technologies) and the image analysis was carried out using ImaGene 8.0 software (BioDiscovery). The quantified signals were background corrected (Normexp with offset value 10) (Ritchie et al., 2007), and normalized using the global Lowess (LOcally WEighted Scatterplot Smoothing) regression algorithm. miRNAs that were more than fourfold differentially expressed were considered for validation by qPCR. Statistical analyses were performed using Student's *t*-tests. RT-PCR for mRNA was carried out using SuperScript II reverse transcriptase (Invitrogen) with random primers, and in RT-PCR for miRNA the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) was used. In both cases, reactions were assembled following the manufacturer's recommendations. qPCR was performed on a LightCycler 480 system (Roche). The universal probe library (Roche) was used for the analysis of mRNA expression. The Taqman microRNA assay (Applied Biosystems) was used for screening the differential expression of miRNAs. qPCR reactions and data analysis were performed as previously described (Carraro et al., 2009). Results are presented as relative expression compared with control. Results were collected from at least three lungs or pools of lungs from independent experiments.

### Culture of embryonic lung explants

Timed-pregnant wild-type or transgenic mice were sacrificed on post-coitum (embryonic) day 11.5 (E11.5), and the embryos were harvested. Lung primordia were placed on 8 µm Nucleopore Track-Etch membranes (Whatman) and cultured in DMEM:F12 medium (Gibco) and 0.5% fetal bovine serum (FBS). Vivo-morpholinos (Gene Tools) were added at 1–4 µM to the lung explants. Recombinant FGF9 and WNT3a (R&D) were added at 200 ng/ml and 250 ng/ml, respectively. The data are representative of at least three lungs from different timed pregnant mice.

### Computational targets prediction

The *miR-142-3p* targets were selected on the basis of the on-line available prediction database miRTar (mirtar.mbc.nctu.edu.tw). The 5'-UTR and the 3'-UTR of target genes were included in the screening. A minimum free energy (MFE) ≤11 Kcal/mol and Score ≥140 were used. A Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis for pathway enrichment was performed.

### β-galactosidase staining

*Axin2*<sup>lacZ</sup> lung explants were fixed in 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) at 4°C for 5 minutes with rocking, washed twice for 5 minutes in PBS at 4°C, then transferred into freshly prepared X-

gal solution and stained at 37°C until a clear precipitate formed; the method was modified from that of Hogan et al. (Hogan et al., 1994). After rinsing with PBS, epithelial explants were post-fixed in 4% PFA in PBS. For vibratome sections, samples were embedded in a mixture of 300 mg/ml albumin, 5 mg/ml gelatin and 0.6% glutaraldehyde, and sectioned. The data are representative of three lungs from independent experiments.

### Immunofluorescence

Tissues were fixed in 4% PFA, gradually dehydrated in ethanol, impregnated with toluene, embedded in paraffin, and sectioned into 5 µm slices on poly-L-lysine-coated slides. Antigen retrieval was performed by boiling the sample for 10 minutes in sodium citrate buffer (10 mM, pH 6.0; Vector). The following antibodies (Abs) were used: APC Ab (Abcam), KI67 Ab (Novabios), phospho-ERK (pERK) Ab (Cell Signaling), phospho-MEK Ab (Cell Signaling), LEF1 Ab (Cell Signaling), phospho-Ser552-CTNNB1 Ab (Cell Signaling), ACTA2 Ab (Sigma), MYH11 Ab (Sigma). All antibodies were used at a 1:200 dilution. The data are representative of at least three lungs from independent experiments.

### Image analysis

Photomicrographs of immunofluorescence staining were taken using a Leica DMRA fluorescence microscope with a Leica digital camera. Live-cell and lung explant time-lapse experiments were performed with a Leica AF6000 fluorescence imaging system. Digital analysis of staining intensity and distribution, and of live-imaging experiments was performed with MetaMorph (Molecular Devices) or ImageJ software. At least three different samples for each condition were analyzed. Phase-contrast images of the samples were recorded using a digital camera (Diagnostic Instruments) connected to a reversed phase-contrast microscope (Leica). The public domain software ImageJ was broadened by routines specifically developed by us and used to process and analyze the images (Guidolin et al., 2004). The number of branches, percentage of tissue area involved in branching, and branching complexity (i.e. the number of branching points of the binary skeleton and the distribution of branching orders) were the morphometric parameters estimated from each sample. Data were processed by using statistical analysis software (GraphPad Prism 3.03, GraphPad Software). The data are representative of at least three lungs from independent experiments.

### miRNA pull-down assay

MLg, MFLM4 or HEK293 cells were cultured in six-well plates and transfected in triplicate with 3'-biotinylated *miR-142-3p* (Bio-miR-142) or 3'-biotinylated scramble (Bio-scramble; Dharmacon), at a final concentration of 30 nM using Lipofectamine RNAimax (Invitrogen) following the manufacturer's protocol. After 48 hours, the cells were pelleted at 1000 rpm for 5 minutes. After washing twice, cell pellets were resuspended in 0.5 ml lysis buffer [50 mM Tris-HCl, 2 mM EDTA, 0.1% NP40, 10% glycerol, 2 mM EGTA, diethylpyrocarbonate (DEPC)-treated water, 50 U RNasin (Promega) and complete mini-protease inhibitor cocktail (Roche Applied Science)], and incubated at 4°C for 10 minutes. The cytoplasmic extract was isolated by centrifugation at 10,000 rpm for 10 minutes. Streptavidin-coated magnetic beads (Invitrogen) were blocked for 1 hour at 4°C in blocking buffer (10 mM Tris-HCl pH 6.5, 1 mM EDTA, 1 mg/ml yeast tRNA and 1 mg/ml BSA) and washed twice with 1 ml washing buffer (10 mM Tris-HCl pH 6.5, 1 mM EDTA 0.5 M NaCl). Beads were resuspended in 0.5 ml washing buffer. Cytoplasmic extract was then added to the beads and incubated for 1 hour at 4°C with slow rotation. The beads were then washed five times with 1 ml washing buffer. RNA bound to the beads (pull-down RNA) or from 10% of the extract (input RNA), was isolated using Trizol reagent LS (Invitrogen). The level of mRNA in the Bio-*miR-142-3p* or Bio-scramble control pull-down was quantified by qPCR. mRNA levels were normalized to a housekeeping gene (*Gapdh*, *H4*). The enrichment ratio of the control-normalized pull-down RNA to the control-normalized input levels was then calculated. The data for each cell line are representative of three independent experiments.

### Luciferase reporter assay

The predicted binding sequence on the 3' UTR of *Apc* was synthetically produced by PCR and transferred into a luciferase reporter vector. To

determine the specificity of the interaction, a reporter vector containing a 'seed' mutated sequence was generated using specific primers. The vector backbone was a pmiRGLO luciferase reporter (Promega) carrying a synthetic firefly luciferase (*luc2*) and a *Renilla* luciferase. Our constructs were inserted downstream of the luciferase gene into a unique *Xba*I restriction site. The *Renilla* luciferase was used as a control to normalize luminescence levels. Experiments were carried out using a dual-luciferase reporter assay system (Promega) and analyzed with a Victor<sup>3</sup> Luminometer (PerkinElmer). The data are representative of three independent experiments.

### Cell culture

For the preparation of primary mesenchymal cells, whole lungs were dissected at E14.5 and subjected to trypsin digestion to give rise to single cells. Mesenchymal cells were separated from epithelial cells by differential adhesion as previously described (Lebeche et al., 1999). Fifty minutes after plating, 200 ng/ml FGF9 was added to the mesenchymal cells. The cells were cultured in DMEM/F12 medium containing penicillin, streptomycin and 0.5% FBS in the presence or absence of FGF9. MFLM4 (Seven Hills), MLg (ATCC) and HEK293 (ATCC) cells were grown in DMEM with 10% FBS. Plasmids expressing GFP (pGFP) and APC (pAPC) were introduced into the cells by electroporation (Lonza). MLg cells were electroporated with 30 nM scramble (scra) or miR-142-3p mimic (mi142) molecules (Dharmacon). The data are representative of three independent experiments.

### Statistical analysis

All data are reported as means  $\pm$  s.d. Statistical analyses were performed using Student's *t*-tests, with  $P \leq 0.05$  considered significant.

### Acknowledgements

We thank Matthew Jones for critical reading of the manuscript.

### Competing interests

The authors declare no competing financial interests.

### Author contributions

G.C. developed the approach, performed experiments and prepared the manuscript. A.S., J.R., A.C., C.C., E.A. and B.M. performed experiments. S.D. and D.G. performed data analysis. M.M.T. and M.E.K. provided mouse lines. W.S. and A.G. edited the manuscript. G.B. and S.D.L. developed the approach and edited the manuscript. S.B. developed the approach and prepared the manuscript prior to submission.

### Funding

This work was supported by the National Institutes of Health (NIH) [RO1 grants HL086322 and HL107307 to S.B., and HL092967 to S.D.L.]; the Excellence Cluster in Cardio-Pulmonary system, Deutsche Forschungsgemeinschaft, LOEWIE (S.B.); LOEWIE [III L 4 – 518/15.004 2009 to G.B.]; and the Deutsche Forschungsgemeinschaft [BA 4036/1-1 to G.B.]. Deposited in PMC for release after 12 months.


### Supplementary material

Supplementary material available online at <http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.105908/-/DC1>

### References


- Brabletz, S. and Brabletz, T. (2010). The ZEB/miR-200 feedback loop – a motor of cellular plasticity in development and cancer? *EMBO Rep.* **11**, 670–677.
- Carraro, G., El-Hashash, A., Guidolin, D., Tiozzo, C., Turcatel, G., Young, B. M., De Langhe, S. P., Bellusci, S., Shi, W., Parnigotto, P. P. et al. (2009). miR-17 family of microRNAs controls FGF10-mediated embryonic lung epithelial branching morphogenesis through MAPK14 and STAT3 regulation of E-Cadherin distribution. *Dev. Biol.* **333**, 238–250.
- Clevers, H. and Nusse, R. (2012). Wnt/ $\beta$ -catenin signaling and disease. *Cell* **149**, 1192–1205.
- Colvin, J. S., White, A. C., Pratt, S. J. and Ornitz, D. M. (2001). Lung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme. *Development* **128**, 2095–2106.
- De Langhe, S. P., Carraro, G., Tefft, D., Li, C., Xu, X., Chai, Y., Minoo, P., Hajihosseini, M. K., Drouin, J., Kaartinen, V. et al. (2008). Formation and differentiation of multiple mesenchymal lineages during lung development is regulated by beta-catenin signalling. *PLoS ONE* **3**, e1516.
- El Agha, E., Al Alam, D., Carraro, G., MacKenzie, B., Goth, K., De Langhe, S. P., Voswinckel, R., Hajihosseini, M. K., Rehan, V. K. and Bellusci, S. (2012). Characterization of a novel fibroblast growth factor 10 (Fgf10) knock-in mouse line to target mesenchymal progenitors during embryonic development. *PLoS ONE* **7**, e38452.
- Fish, J. E., Santoro, M. M., Morton, S. U., Yu, S., Yeh, R. F., Wythe, J. D., Ivey, K. N., Bruneau, B. G., Stainier, D. Y. and Srivastava, D. (2008). miR-126 regulates angiogenic signaling and vascular integrity. *Dev. Cell* **15**, 272–284.
- Groden, J., Thliveris, A., Samowitz, W., Carlson, M., Gelbert, L., Albertsen, H., Joslyn, G., Stevens, J., Spirio, L., Robertson, M. et al. (1991). Identification and characterization of the familial adenomatous polyposis coli gene. *Cell* **66**, 589–600.
- Guidolin, D., Vacca, A., Nussdorfer, G. G. and Ribatti, D. (2004). A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. *Microvasc. Res.* **67**, 117–124.
- Harada, N., Tamai, Y., Ishikawa, T., Sauer, B., Takaku, K., Oshima, M. and Taketo, M. M. (1999). Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. *EMBO J.* **18**, 5931–5942.
- He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B. and Kinzler, K. W. (1998). Identification of c-MYC as a target of the APC pathway. *Science* **281**, 1509–1512.
- Hogan, B. L., Blessing, M., Winnier, G. E., Suzuki, N. and Jones, C. M. (1994). Growth factors in development: the role of TGF-beta related polypeptide signalling molecules in embryogenesis. *Dev. Suppl.* **1994**, 53–60.
- Jiang, Q., Hao, Y., Wang, G., Juan, L., Zhang, T., Teng, M., Liu, Y. and Wang, Y. (2010). Prioritization of disease microRNAs through a human phenome-microRNAome network. *BMC Syst. Biol.* **4** Suppl. 1, S2.
- Kaduthanam, S., Gade, S., Meister, M., Brase, J. C., Johannes, M., Dienemann, H., Warth, A., Schnabel, P. A., Herth, F. J., Sultmann, H. et al. (2013). Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. *Lung Cancer* **80**, 223–227.
- Lebeche, D., Malpel, S. and Cardoso, W. V. (1999). Fibroblast growth factor interactions in the developing lung. *Mech. Dev.* **86**, 125–136.
- Lu, Y., Thomson, J. M., Wong, H. Y., Hammond, S. M. and Hogan, B. L. (2007). Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. *Dev. Biol.* **310**, 442–453.
- Lv, M., Zhang, X., Jia, H., Li, D., Zhang, B., Zhang, H., Hong, M., Jiang, T., Jiang, Q., Lu, J. et al. (2012). An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor- $\alpha$  and cAMP/PKA pathways. *Leukemia* **26**, 769–777.
- Mailleux, A. A., Kelly, R., Veltmaat, J. M., De Langhe, S. P., Zaffran, S., Thiery, J. P. and Bellusci, S. (2005). Fgf10 expression identifies parabronchial smooth muscle cell progenitors and is required for their entry into the smooth muscle cell lineage. *Development* **132**, 2157–2166.
- Neilson, J. R., Zheng, G. X., Burge, C. B. and Sharp, P. A. (2007). Dynamic regulation of miRNA expression in ordered stages of cellular development. *Genes Dev.* **21**, 578–589.
- Niehhs, C. and Aeberson, S. P. (2012). Mitotic and mitogenic Wnt signalling. *EMBO J.* **31**, 2705–2713.
- Nimmo, R., Cia-Uitz, A., Ruiz-Herguido, C., Soneji, S., Bigas, A., Patient, R. and Enver, T. (2013). MiR-142-3p controls the specification of definitive hemangioblasts during ontogeny. *Dev. Cell* **26**, 237–249.
- Ornitz, D. M. and Yin, Y. (2012). Signaling networks regulating development of the lower respiratory tract. *Cold Spring Harb. Perspect. Biol.* **4**.
- Oshima, H., Oshima, M., Kobayashi, M., Tsutsumi, M. and Taketo, M. M. (1997). Morphological and molecular processes of polyp formation in *Apc(delta716)* knock-out mice. *Cancer Res.* **57**, 1644–1649.
- Rasmussen, K. D., Simmini, S., Abreu-Goodger, C., Bartonicek, N., Di Giacomo, M., Bilbao-Cortes, D., Horos, R., Von Lindern, M., Enright, A. J. and O'Carroll, D. (2010). The miR-144/451 locus is required for erythroid homeostasis. *J. Exp. Med.* **207**, 1351–1358.
- Ritchie, M. E., Silver, J., Oshlack, A., Holmes, M., Diyagama, D., Holloway, A. and Smyth, G. K. (2007). A comparison of background correction methods for two-colour microarrays. *Bioinformatics* **23**, 2700–2707.
- Tian, Y., Zhang, Y., Hurd, L., Hannehalli, S., Liu, F., Lu, M. M. and Morrissey, E. E. (2011). Regulation of lung endoderm progenitor cell behavior by miR302/367. *Development* **138**, 1235–1245.
- van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A. P. et al. (2002). The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. *Cell* **111**, 241–250.
- Van Scoyk, M., Randall, J., Sergew, A., Williams, L. M., Tennis, M. and Winn, R. A. (2008). Wnt signaling pathway and lung disease. *Transl. Res.* **151**, 175–180.
- Ventura, A., Young, A. G., Winslow, M. M., Lintault, L., Meissner, A., Erkeland, S. J., Newman, J., Bronson, R. T., Crowley, D., Stone, J. R. et al. (2008). Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. *Cell* **132**, 875–886.
- Wang, Y., Huang, C., Reddy Chintagari, N., Bhaskaran, M., Weng, T., Guo, Y., Xiao, X. and Liu, L. (2013). miR-375 regulates rat alveolar epithelial cell trans-differentiation by inhibiting Wnt/ $\beta$ -catenin pathway. *Nucleic Acids Res.* **41**, 3833–3844.
- Yi, L., Domyan, E. T., Lewandoski, M. and Sun, X. (2009). Fibroblast growth factor 9 signaling inhibits airway smooth muscle differentiation in mouse lung. *Dev. Dyn.* **238**, 123–137.
- Yin, Y., White, A. C., Huh, S. H., Hilton, M. J., Kanazawa, H., Long, F. and Ornitz, D. M. (2008). An FGF-WNT gene regulatory network controls lung mesenchyme development. *Dev. Biol.* **319**, 426–436.
- Yin, Y., Wang, F. and Ornitz, D. M. (2011). Mesothelial- and epithelial-derived FGF9 have distinct functions in the regulation of lung development. *Development* **138**, 3169–3177.






**Figure S1. Validation of the vivo-morpholino LOF assay.** (A-H) Morphometric changes on E11.5 lung explants administrated with scramble (scra; A,E), mo126 (B,F), mo144 (C,G), mo142 (D,H), and its relative quantification of branching (I). (J-M) Immunostaining for PECAM1 showing vasculature formation in E11.5 lung explants treated with scra (J,L) and mo126 (K,M). (R) Quantification of the vasculature ramification calculated as numbers of intercepts across terminal buds. (N-Q) Immunostaining for Ki67 showing cell proliferation in mo144 (N,P) and mo142 (O,Q) treated lungs. White boxes indicate the magnified areas in the lower panels. Dashed lines demarcate the epithelium-mesenchyme boundary. (S) Quantification of proliferation in the mesenchyme of mo144 and mo142 treated lungs. Scale bars: 1.2 mm (A-D); 250  $\mu$ m (E-H,J,K); 35  $\mu$ m (L,M); 100  $\mu$ m (N,O); 50  $\mu$ m (P,Q); Data are means  $\pm$  s.d.






**Figure S2. Pull-down assay for *miR-142-3p* on HEK293 and MFLM4 cells.** (A,B) WNT signaling related gene expression is shown by qPCR after transfection of HEK293 cells (A) and MFLM4 cells (B) with biotinylated *miR-142-3p*. Data are normalized against biotinylated scramble. (C,D) *Apc* enrichment after pull-down assay on HEK293 cells and MFLM4 cells is shown by qPCR. Data are means  $\pm$  s.d.




**Figure S3. Rescue experiments for *miR-142-3p* LOF assay.** (A-H) Analysis of the effect of FGF9 and WNT3a during *miR-142-3p* LOF assay. Bright field images of E11.5 lung explants (A,B,E,F) and morphometric analysis (C,D,G,H) are shown after treatment with WNT3a or a combination of FGF9 and WNT3a. Immunofluorescence for MYH11 (I-L) and CTNNB1 phosphorylated at serine-552 (M-P) are shown after *miR-142-3p* LOF assay performed on E11.5 lung explants harboring activated CTNNB1. Dashed lines demarcate the epithelium-mesenchyme boundary. Scale bars: 250 μm (A,B,E,F); 75 μm (I,K,M,O); 25 μm (J,L,N,P). Data are means ± s.d.



**Movie 1.** Bright field time-lapse microscopy of the branching lung is shown in control (scramble) and after *miR-142-3p* knockdown (mo142). Scramble and mo142 treated lungs were analyzed for 45 hours.



**Movie 2.** Fluorescence time-lapse microscopy of *Fgf10<sup>RFP</sup>* lungs explants after *miR-142-3p* LOF assay is shown. Control (scramble) and treated (mo142) lungs were analyzed for 20 hours (top row). Scramble and mo142 treated lungs are shown in high magnification for an additional 20 hours (bottom row).



**Movie 3.** Bright field and fluorescence time-lapse microscopy of primary culture of mesenchymal cells isolated from *Fgf10<sup>RFP</sup>* lungs electroporated with *Apc* (pAPC) or control *Gfp* (pGFP) plasmids.